Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Nagoya Journal of Medical Science|September 23, 2021
A case of sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance: long-term observation of neurological symptoms after autologous stem-cell transplantationTakashi Ando, Takahiko Sato, Shingo Kurahashi, et al.
Cytotherapy|June 17, 2025
Adjustment of low-dose ATG exposure improves outcomes in allogeneic hematopoietic stem cell transplantation: a prospective multicenter studyShihomi Kuwano, Seitaro Terakura, Kanae Imai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in JapanChika Kawajiri-Manako, Emiko Sakaida, Chikako Ohwada, et al.
Medicine|February 1, 2018
Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study)Satoshi Nishiwaki, Isamu Sugiura, Yasuhiko Miyata, et al.
American Journal of Hematology|February 5, 2024
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remissionSatoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, et al.
Ejhaem|May 19, 2023
Autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia is safe but poses challenges for long-term maintenance of molecular remission: Results of the Auto-Ph17 studySatoshi Nishiwaki, Isamu Sugiura, Takahiko Sato, et al.
Annals of Hematology|February 15, 2015
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapseNobuhiko Imahashi, Haruhiko Ohashi, Seitaro Terakura, et al.
International Journal of Hematology|August 27, 2025
Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial dataSatoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, et al.
International Journal of Hematology|July 30, 2021
Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapyShinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, et al.
International Journal of Hematology|November 25, 2024
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit studyTsuyoshi Muta, Yosuke Masamoto, Go Yamamoto, et al.
Pageof 6